Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: February 7, 2023

Details for Patent: 8,998,876

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,998,876 protect, and when does it expire?

Patent 8,998,876 protects BYDUREON PEN and is included in one NDA.

Protection for BYDUREON PEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seven patent family members in four countries.

Summary for Patent: 8,998,876
Title:Ampoule comprising an ampoule holder
Abstract: An ampoule holder for receiving an ampoule that has a closure element with a radial projection, the ampoule holder including an ampoule seat and a securing member operably coupled to the ampoule seat, wherein the radial projection of the closure element can be arranged between the ampoule seat and securing member.
Inventor(s): Drunk; Annette (Bern, CH), Buttler; Marius (Oensingen, CH), Schiffmann; Frank (Burgdorf, CH), Tretola; Sara (Biberist, CH), Weber; Kurt (Bolken, CH), Moser; Ulrich (Heimiswil, CH), Hirschel; Jurg (Aarau, CH)
Assignee: TecPharma Licensing AG (Burgdorf, CH)
Application Number:12/951,804
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,998,876

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,998,876

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2008 025 011May 24, 2008

International Family Members for US Patent 8,998,876

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 102008025011 See Plans and Pricing
European Patent Office 2300079 See Plans and Pricing
European Patent Office 2300081 See Plans and Pricing
Taiwan 200948408 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.